LADENBURG THALM/SH SH began coverage on shares of NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) in a research report released on Wednesday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $1.10 target price on the biopharmaceutical company’s stock.

Shares of NovaBay Pharmaceuticals stock opened at $0.69 on Wednesday. NovaBay Pharmaceuticals has a 12 month low of $0.23 and a 12 month high of $4.04.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter. The firm had revenue of $1.79 million during the quarter.

A hedge fund recently raised its stake in NovaBay Pharmaceuticals stock. Renaissance Technologies LLC grew its position in shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) by 1,283.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 412,469 shares of the biopharmaceutical company’s stock after purchasing an additional 382,645 shares during the quarter. Renaissance Technologies LLC owned approximately 1.96% of NovaBay Pharmaceuticals worth $697,000 as of its most recent SEC filing.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Featured Article: How to Invest in a Bull Market

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.